Floatz logo

Itraconazole

Castrate-resistant Prostate Cancer (CRPC)

PfizerPhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

229 Active assets in the Castrate-resistant Prostate Cancer (CRPC) cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
RADIUM RA-223
Bayer
Phase 4BB

View all 50 →

Same molecule, other indications

Itraconazole is also rated in:

retinoblastomaDormant
BB
Indicative ·
68 / 100
View asset →
fungal infectious diseaseDormant
BB
Indicative ·
68 / 100
View asset →
Wilms tumorDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →